Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Competing Budget Aims: Frugality Versus Launching New Initiatives

Executive Summary

FDA's proposed fiscal year 2012 budget provides a modest 7% increase in federal appropriations for the human drugs program, which also will benefit from a hefty 46% increase in PDUFA user fees.

You may also be interested in...



FDA's Hamburg Says Japanese Crisis Shows Need To Fund Countermeasure Development

When Senators ask whether the U.S. is prepared for a nuclear disaster similar to one following the Japanese earthquake, FDA chief touts agency program that could help develop radiation treatments.

U.S. FDA Globalization Efforts Gain Traction Even As Budget Request Emphasizes Old Inspection Model

U.S. FDA would gain a boost in funding for overseas manufacturing facility inspections in President Obama's fiscal year 2012 budget, even though the agency has acknowledged its model is unsustainable and is planning changes

FDA Globalization Efforts Gain Traction Even As Budget Request Emphasizes Old Inspection Model

FDA would gain a boost in funding for overseas manufacturing facility inspections in President Obama’s fiscal year 2012 budget, even though the agency has acknowledged its model is unsustainable and is planning changes.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053144

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel